Anales de la RANM

163 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 OBESIDADES INFANTILES: DIAGNÓSTICO Y TRATAMIENTO Martos-Moreno GA, et al. An RANM. 2024;141(02): 155 - 163 36. Haqq AM, Chung WK, Dollfus H, Haws RM, Mar- tos-Moreno GÁ, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol 2022; 10 :859- 868. DOI: 10.1016/S2213-8587(22)00277-7. 37. Kelly AS, Auerbach P, Barrientos-Perez M, et al; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020; 382: 2117-2128. DOI: 10.1056/NEJMoa1916038. 38. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-Weekly Semaglu- tide in Adolescents with Obesity.N Engl J Med 2022; 387: 2245-2257. DOI: 10.1056/NEJMoa2208601. 39. Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, et al. Phentermine/Topirama- te for the Treatment of Adolescent Obesity. NEJM Evidence 2022; 1. DOI: https://doi.org/10.1056/EVI- Doa2200014. 40. Chanoine JP, Hampl S, Jensen C, Boldrin M, Haupt- man J. Effect of orlistat on weight and body compo- sition in obese adolescents: a randomized contro- lled trial. JAMA 2005; 293: 2873-83. doi: 10.1001/ jama.293.23.2873. 41. Wang DD, Mao YZ, He SM, Chen X. Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents. Front Pharmacol 2021; 12: 611480. DOI: 10.3389/ fphar.2021.611480. 42. Torbahn G, Jones A, Griffiths A, Matu J, Metzendorf MI, Ells LJ, et al. Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.Pediatr Obes 2024; 19: e13113. DOI: 10.1111/ijpo.13113. 43. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once wee- kly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, ran- domised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402: 613-626. DOI: 10.1016/ S0140-6736(23)01200-X. Si desea citar nuestro artículo: Martos-Moreno GA, Argente J. Obesidades infantiles: diagnóstico y tratamiento. An RANM. 2024;141(02): 155–163. DOI: 10.32440/ ar.2024.141.02. rev 07